From SA: CytoDyn on go with UK late-stage study
Post# of 148155
CytoDyn on go with UK late-stage study of leronlimab for COVID-19
Aug. 20, 2020 6:30 AM ET|About: CytoDyn Inc. (CYDY)|By: Douglas W. House, SA News Editor
The UK's Medicines and Healthcare products Regulatory Agency has signed off on a Phase 3 clinical trial evaluating CytDyn's (OTCQB:CYDY) leronlimab in severely and critically ill COVID-19 patients.
Yesterday, it requested Fast Track approval of the drug based on the results from a mid-stage study.